Cargando…

Neurobiology of depression : road to novel therapeutics /

Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and th...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Quevedo, Jo�ao (Editor ), Carvalho, Andr�e F. (Editor ), Zarate, Carlos A., Jr (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London, United Kingdom ; San Diego, CA : Academic Press, an imprint of Elsevier, [2019]
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 SCIDIR_on1081173641
003 OCoLC
005 20231120010336.0
006 m o d
007 cr cnu---unuuu
008 190108s2019 enk ob 001 0 eng d
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d N$T  |d YDX  |d EBLCP  |d UKMGB  |d OCLCF  |d CNCGM  |d OUP  |d YDXIT  |d OCLCQ  |d TEF  |d OPELS  |d OCLCQ  |d S2H  |d OCLCO  |d LVT  |d UX1  |d VT2  |d OCLCA  |d OCLCO  |d OCLCQ  |d OCLCO  |d COM  |d OCLCQ  |d SFB  |d OCLCQ  |d OCLCO 
015 |a GBB913023  |2 bnb 
016 7 |a 019207282  |2 Uk 
019 |a 1081383934  |a 1082186920  |a 1229742440  |a 1235843404 
020 |a 9780128133347  |q (electronic book) 
020 |a 0128133341  |q (electronic book) 
020 |z 9780128133330 
020 |z 0128133333 
035 |a (OCoLC)1081173641  |z (OCoLC)1081383934  |z (OCoLC)1082186920  |z (OCoLC)1229742440  |z (OCoLC)1235843404 
050 4 |a RC537  |b .N487 2019 
060 4 |a 2019 C-900 
060 4 |a WM 171.5 
072 7 |a HEA  |x 039000  |2 bisacsh 
072 7 |a MED  |x 014000  |2 bisacsh 
072 7 |a MED  |x 022000  |2 bisacsh 
072 7 |a MED  |x 112000  |2 bisacsh 
072 7 |a MED  |x 045000  |2 bisacsh 
082 0 4 |a 616.85/27  |2 23 
245 0 0 |a Neurobiology of depression :  |b road to novel therapeutics /  |c edited by Jo�ao Quevedo, Andr�e F. Carvalho, Carlos A. Zarate. 
264 1 |a London, United Kingdom ;  |a San Diego, CA :  |b Academic Press, an imprint of Elsevier,  |c [2019] 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
504 |a Includes bibliographical references and index. 
505 0 |a Front Cover; Neurobiology of Depression: Road to Novel Therapeutics; Copyright; Contents; Contributors; Chapter 1: The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC; Funding; Conflict of Interest; Acknowledgments; References; Chapter 2: The Role of Environmental and Psychosocial Factors in Depression; Introduction; Some Consideration of ``Depression��; Depressogenic Factors; Impact of Cognitive Style; Mechanisms Linking Psychosocial Stressors With Depression: The Centrality of Self-Esteem; Depressogenic Stressors; Depression Versus Grief 
505 8 |a The Role of PersonalityKeys and Locks: ``Swiss Cheese�� and a Lacunae Self-Esteem; Conclusions; Acknowledgments; References; Chapter 3: Gene-Environment Interactions and Epigenetic Mechanisms in Depression; Introduction; Gene x Environment Effects (Candidate Genes); Candidate Genes Within the Serotonergic System; Serotonin Transporter Polymorphism (SLC6A4); GxE Effects in BDNF Function in MDD; GxE Effects in HPA Dysregulation in MDD; GxE Effects: FKBP5 Gene; GxE Effects: CRHR1; Epigenetic Mechanisms Modulating Environmental Effects 
505 8 |a Epigenetic Mechanisms Modulating Serotonin Transporter Gene ExpressionEpigenetic Mechanisms Modulating BDNF Gene Expression; Epigenetic Mechanisms in the Regulation of Genes Within the HPA Axis; Genome-Wide GenexEnvironment Effects; Discussion; References; Chapter 4: Pathophysiology of Cognitive Impairment in Depression; Executive Functioning; Working Memory; Memory; References; Further Reading; Chapter 5: Anhedonia in Depression: Mechanisms, Assessment, and Therapeutics; Introduction; Anhedonia: A Brief Historical Context; Anhedonia and Vulnerability to Major Depression 
505 8 |a Neural Mechanisms of Anhedonia and DepressionMultifactorial Influences on Striatal Responding and Mood; Environment; Assessment; Therapeutics; Conclusions; Conflict of Interest; Acknowledgments; References; Chapter 6: The Neurotrophic Hypothesis of Depression Revisited: New Insights and Therapeutic Implications; Introduction; Brain-Derived Neurotrophic Factor (BDNF); Role of BDNF in the Effects of Chronic Stress; Regulation of BDNF by Stress; Contribution of BDNF to Stress-Evoked Cytoarchitectural Changes; Contribution of BDNF to Stress-Induced Depressive-like Behavior 
505 8 |a Role of BDNF in Antidepressant ActionRegulation of BDNF by Antidepressants; Contribution of BDNF to Antidepressant-Evoked Cytoarchitectural Changes; Influence of BDNF Signaling on Antidepressant-Mediated Behaviors; Clinical Studies; Regulation of BDNF in Depressed Patients; Regulation of BDNF Expression in Response to Antidepressant Treatment; BDNF Polymorphisms; Summary; References; Chapter 7: The Monoamine Hypothesis of Depression Revisited: Could It Mechanistically Novel Antidepressant Strategies?; The Monoamine Hypothesis; Serotonin-Noradrenaline; Dopamine; Withdrawal from Antidepressants 
588 0 |a Online resource; title from digital title page (viewed on May 13, 2019). 
520 |a Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD. Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness. 
650 0 |a Depression, Mental  |x Pathophysiology. 
650 0 |a Neurobiology. 
650 1 2 |a Depressive Disorder  |0 (DNLM)D003866 
650 2 |a Neurobiology  |0 (DNLM)D009446 
650 6 |a D�epression  |0 (CaQQLa)201-0007222  |x Physiopathologie.  |0 (CaQQLa)201-0379296 
650 6 |a Neurobiologie.  |0 (CaQQLa)201-0010246 
650 7 |a HEALTH & FITNESS  |x Diseases  |x General.  |2 bisacsh 
650 7 |a MEDICAL  |x Clinical Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Diseases.  |2 bisacsh 
650 7 |a MEDICAL  |x Evidence-Based Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Internal Medicine.  |2 bisacsh 
650 7 |a Depression, Mental  |x Pathophysiology  |2 fast  |0 (OCoLC)fst00890949 
650 7 |a Neurobiology  |2 fast  |0 (OCoLC)fst01036315 
700 1 |a Quevedo, Jo�ao,  |e editor. 
700 1 |a Carvalho, Andr�e F.,  |e editor. 
700 1 |a Zarate, Carlos A.,  |c Jr.,  |e editor. 
776 0 8 |i Print version:  |t NEUROBIOLOGY OF DEPRESSION.  |d [Place of publication not identified], ELSEVIER ACADEMIC Press, 2019  |z 0128133333  |w (OCoLC)1047822936 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780128133330  |z Texto completo